The criminal prosecution of Purdue Pharma generated a blockbuster $600 million global settlement resolving government and private claims rooted in the company’s unlawful promotion of the painkiller OxyContin as a safer, less addictive alternative to other drugs.
Former Purdue chief executive officer Michael Friedman, general counsel Howard Udell and medical director Paul Goldenheim agreed in separate deals to give up $34.5 million in profits and to serve three years of probation. But each lost something more: effectively, the ability to work in the pharmaceutical and health care industries.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
